Can a smaller dose of a drug ease the pain of pregnancy loss?
NCT ID NCT06909123
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests whether a lower dose of cabergoline can safely prevent lactation and breast discomfort after second-trimester abortion or pregnancy loss. The standard dose works but can be costly and cause side effects. Researchers will enroll 36 people to compare the reduced dose with the usual dose, using blood tests and symptom surveys.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LACTATION SUPPRESSED are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabergoline (Dostinex)
What this could lead to
If successful, this could provide a cheaper, more tolerable option to prevent breast pain and milk production after second-trimester pregnancy loss or abortion.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The reduced dose might be less effective at stopping lactation.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.